It takes a sugar to catch a sugar

Figure 1: GLUT4 is normally retained within storage vesicles in the cytoplasm (top left), but is redistributed to the cell membrane within 30 minutes of insulin treatment (top right). However, the non-glycosylated N57Q mutant (bottom left) fails to respond to insulin and remains within cytoplasmic vesicles even after 30 minutes (bottom right) (scale bars, 10 μm). Credit: Reproduced from Ref. 1 © 2011 American Society for Biochemistry and Molecular Biology

After every meal, the hormone insulin is released into the bloodstream, issuing instructions to target cells to begin taking up excess sugar. In some situations, however, cells stop responding to these signals; and this insulin-resistant state is associated with onset of type 2 diabetes. Unexpected findings from Tadashi Suzuki’s group at the RIKEN Advanced Science Institute in Wako have now revealed how a cellular malfunction may contribute to this insulin resistance. 

Suzuki and postdoctoral fellow Yoshimi Haga had originally sought to develop imaging strategies to track localization of proteins modified with carbohydrate groups in a process known as glycosylation. They tested their method with the glucose-transporter GLUT4 and developed a mutant version of the protein that lacks a glycosylation site, but the results led their study in a new direction. “We accidentally found that behavior of our N57Q mutant and the wild-type protein was quite different,” says Suzuki. “It was a completely serendipitous finding.” 

Insulin-responsive typically maintain reservoirs of GLUT4 in bubble-like vesicles within the cytoplasm; insulin signals induce the transport of GLUT 4 to the cell surface, where it begins pumping glucose into the cell. The N57Q mutant, on the other hand, was largely unresponsive to insulin (Fig. 1). Suzuki and colleagues determined that, instead of gathering within storage vesicles, this protein tended to accumulate either at the cell surface or within ‘recycling vesicles’ that continually shuttle to and away from the plasma membrane.

The N57Q mutant retains normal glucose-transporting capabilities, suggesting that this modification acts primarily as a trafficking signal rather than influencing protein function. Accordingly, the researchers observed the same insulin-insensitive behavior when they used a chemical treatment to alter the glycosylation of normal GLUT4. “These results clearly suggest that there must be a mechanism that detects subtle differences in glycan structure on this protein to sort it into specific GLUT4 vesicles,” says Suzuki.

Several studies have found evidence that GLUT4 may be subject to altered glycosylation in a subset of patients with ; and, these new findings provide a potential explanation for how malfunctions in this protein modification process could contribute to pathology. As a next step, Suzuki hopes to uncover more details about how this transport pathway intersects with the insulin response. “We believe that glycan-recognition molecules known as lectins should be involved in this process,” he says, “and we will try to identify these lectins and other players involved in the fine-tuning of intracellular trafficking of GLUT4.”

More information: Haga, Y., Ishii, K. & Suzuki, T. N-glycosylation is critical for the stability and intracellular trafficking of GLUT4 glucose transporter. The Journal of Biological Chemistry published online 14 July 2011. doi: 10.1074/jbc.M111.253955

add to favorites email to friend print save as pdf

Related Stories

Glucose uptake relies on newly identified protein

Sep 06, 2011

All cells need glucose (sugar) to produce the energy they need to survive. High glucose levels in the bloodstream (such as occur after a meal), trigger the pancreas to produce insulin. In turn, muscle and ...

Completely novel action of insulin unveiled

Nov 05, 2008

A PhD student at Sydney's Garvan Institute of Medical Research has uncovered an important piece in the puzzle of how insulin works, a problem that has plagued researchers for more than 50 years. This finding brings us one ...

Recommended for you

A better way to track emerging cell therapies using MRIs

Sep 19, 2014

Cellular therapeutics – using intact cells to treat and cure disease – is a hugely promising new approach in medicine but it is hindered by the inability of doctors and scientists to effectively track the movements, destination ...

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

DanielHaszard
not rated yet Dec 03, 2011
Be aware of drugs that potentiate diabetes.
Eli Lilly Zyprexa Olanzapine issues linger.
The use of powerful antipsychotic drugs has increased in children as young as three years old. Weight gain, increases in triglyceride levels and associated risks for diabetes and cardiovascular disease. The average weight gain (adults) over the 12 week study period was the highest for Zyprexa17 pounds. Youd be hard pressed to gain that kind of weight sport-eating your way through the holidays.One in 145 adults died in clinical trials of those taking the antipsychotic drug Zyprexa.
This was Lilly's #1 product $5 billion per year sales,moreover Lilly also make billions more on drugs that treat diabetes.
--- Daniel Haszard Zyprexa activist and patient.